Heterocyclic scaffolds targeting IDO1: progress in medicinal chemistry and clinical development. (PubMed, Future Med Chem) - Oct 1, 2026 - "IDO1 inhibitors were classified into diverse scaffolds, including indoles, imidazoles, phenyl urea-benzimidazoles, azoles, imidazopyridines, benzofurans, quinolines, pyrimidines, erlotinib-based analogues, naphthoquinones, hydroxyamidine derivatives, quinazolines, and sulfonamide chromone-oxime analogues. Clinically investigated inhibitors such as indoximod, epacadostat, navoximod, LY3381916, linrodostat, and PF-06840003 were also evaluated for therapeutic outcomes. This review provides an updated overview of IDO1 inhibitor design and development, offering valuable insights into scaffold optimization and future directions for developing effective anticancer agents targeting tumor immunosuppression."
Journal • Review • Oncology • IDO1
|
|
Ankush Kumar; Rajiv Patel; Rajwinder Kaur; Rohit Bhatia; Vishakha Sharma
|